Charles River Laboratories International (CRL)
(Real Time Quote from BATS)
$232.97 USD
+3.94 (1.72%)
Updated Apr 29, 2024 11:58 AM ET
3-Hold of 5 3
C Value C Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRL 232.97 +3.94(1.72%)
Will CRL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
ICLR vs. CRL: Which Stock Is the Better Value Option?
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Other News for CRL
Iterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem
With rate cuts pushed out, Goldman looks at quality stocks
Danaher Q1: The Worst Time Has Already Passed
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing